StockData
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. (CMMB) stock

CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 5/30
$1.14−0.41 (-26.45%)

Close on Nov 19, 2026Market cap $8.20MP/E 0.8Yield –

Chemomab Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Chemomab Therapeutics's free cash flow for the twelve months ending Jun 30, 2023 was -$25.68M. For fiscal 2025 it was -$11.13M. The highest annual figure on record is -$3.81M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.13M–
FY2024Dec 31, 2024-$15.39M–
FY2023Dec 31, 2023-$23.61M–
FY2022Dec 31, 2022-$20.44M–
FY2021Dec 31, 2021-$12.61M–
FY2020Dec 31, 2020-$5.28M–
FY2019Dec 31, 2019-$16.55M–
FY2018Dec 31, 2018-$14.44M–
FY2017Dec 31, 2017-$8.55M–
FY2016Dec 31, 2016-$3.81M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023-$7.49M–
Q1 FY2023Mar 31, 2023-$7.19M–
Q4 FY2022Dec 31, 2022-$5.70M–
Q3 FY2022Sep 30, 2022-$5.30M–
Q2 FY2022Jun 30, 2022-$5.71M–
Q1 FY2022Mar 31, 2022-$3.73M–
Q4 FY2021Dec 31, 2021-$3.03M–
Q3 FY2021Sep 30, 2021-$2.58M–
Q2 FY2021Jun 30, 2021-$5.71M–
Q1 FY2021Mar 31, 2021-$1.30M–
Q4 FY2020Dec 31, 2020-$1.56M–
Q3 FY2020Sep 30, 2020-$921.00K–
Q2 FY2020Jun 30, 2020-$880.00K–
Q1 FY2020Mar 31, 2020-$1.92M–
Q4 FY2019Dec 31, 2019-$5.66M–
Q3 FY2019Sep 30, 2019-$3.76M–
Q2 FY2019Jun 30, 2019-$3.93M–
Q1 FY2019Mar 31, 2019-$3.20M–

More Chemomab Therapeutics figures

See a number that looks wrong?